Flora Growth Q1 2023 Earnings Report

Flora Growth EPS Results

• Actual EPS: -$0.03
• Consensus EPS: -$0.04
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Flora Growth Revenue Results

• Actual Revenue: $20.11 million
• Expected Revenue: $22.96 million
• Beat/Miss: Missed by -$2.85 million
• YoY Revenue Growth: N/A

Flora Growth Announcement Details

• Quarter: Q1 2023
• Date: 5/15/2023
• Time: N/A

Flora Growth (NASDAQ:FLGC), together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.